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The extracellular matrix comprises a network of macromolecules such as collagens, proteoglycans and glycoproteins. VWA1 (von
Willebrand factor A domain containing 1) encodes a component of the extracellular matrix that interacts with perlecan/collagen VI,
appears to be involved in stabilizing extracellular matrix structures, and demonstrates high expression levels in tibial nerve. Vwa1-defi-
cient mice manifest with abnormal peripheral nerve structure/function; however, VWA1 variants have not previously been associated
with human disease. By interrogating the genome sequences of 74 180 individuals from the 100K Genomes Project in combination
with international gene-matching efforts and targeted sequencing, we identified 17 individuals from 15 families with an autosomal-re-
cessive, non-length dependent, hereditary motor neuropathy and rare biallelic variants in VWA1. A single disease-associated allele
p.(G25Rfs*74), a 10-bp repeat expansion, was observed in 14/15 families and was homozygous in 10/15. Given an allele frequency
in European populations approaching 1/1000, the seven unrelated homozygote individuals ascertained from the 100K Genomes
Project represents a substantial enrichment above expected. Haplotype analysis identified a shared 220 kb region suggesting that this
founder mutation arose 47000 years ago. A wide age-range of patients (6–83 years) helped delineate the clinical phenotype over
time. The commonest disease presentation in the cohort was an early-onset (mean 2.0±1.4 years) non-length-dependent axonal her-
editary motor neuropathy, confirmed on electrophysiology, which will have to be differentiated from other predominantly or pure
motor neuropathies and neuronopathies. Because of slow disease progression, ambulation was largely preserved. Neurophysiology,
muscle histopathology, and muscle MRI findings typically revealed clear neurogenic changes with single isolated cases displaying add-
itional myopathic process. We speculate that a few findings of myopathic changes might be secondary to chronic denervation rather
than indicating an additional myopathic disease process. Duplex reverse transcription polymerase chain reaction and immunoblotting
using patient fibroblasts revealed that the founder allele results in partial nonsense mediated decay and an absence of detectable
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protein. CRISPR and morpholino vwa1 modelling in zebrafish demonstrated reductions in motor neuron axonal growth, synaptic for-
mation in the skeletal muscles and locomotive behaviour. In summary, we estimate that biallelic variants in VWA1 may be responsible
for up to 1% of unexplained hereditary motor neuropathy cases in Europeans. The detailed clinical characterization provided here
will facilitate targeted testing on suitable patient cohorts. This novel disease gene may have previously evaded detection because of
high GC content, consequential low coverage and computational difficulties associated with robustly detecting repeat-expansions.
Reviewing previously unsolved exomes using lower QC filters may generate further diagnoses.
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Introduction
The extracellular matrix (ECM) is a structural and regula-
tory network of glycoproteins and other macromolecules
that plays an important role in connective tissue rich struc-
tures such as bone, tendon and skin. The ECM is also im-
portant for development and maintenance of the
peripheral nervous system including nerve, the neuromus-
cular junction and muscle. The composition of the ECM
varies for different tissues and is highly dynamic. Well-
known disease-associated ECM constituents within the
peripheral nervous system include perlecan, laminins, col-
lagen Q, collagen XII and collagen VI, which are involved
in various aspects of muscle, nerve and neuromuscular
junction function and integrity.
In humans, VWA1 (von Willebrand factor A domain con-
taining 1) encodes a 445 amino acid ECM protein that is
also referred to as von Willebrand factor A domain related
protein (WARP). Two fibronectin type III repeats are situ-
ated downstream of the von Willebrand factor A (VWFA)
domain. Reporter gene assays indicated that Vwa1 is
expressed not only in cartilage but also in the basement
membrane structures of the peripheral nervous system (Allen
et al., 2008). The WARP protein is thought to interact with
perlecan and also type VI collagen. In WARP-deficient mice
there is compromised function of peripheral nerves and
collagen VI is reduced in regions of the peripheral nerve
ECM (Allen et al., 2009). Transmission electron microscopy
of sciatic nerve tissues taken from the WARP-deficient mice
revealed an unusual partial fusion of the basement mem-
branes of neighbouring axons (Allen et al., 2009). In
humans, pathogenic variants in collagen 6 (COL6A1–3)
genes cause COL-6-related dystrophies (COL6-RDs) ranging
from the severe Ullrich congenital muscular dystrophy
(MIM #254090), to intermediate phenotypes and Bethlem
muscular dystrophy at the milder end of the spectrum (MIM
#158810).
Human gene expression data (GTEx Consortium, 2015)
indicate that VWA1 shows highest expression levels in tib-
ial nerve (Supplementary Fig. 1A). Other well-known dis-
ease genes PMP22 (MIM *601097) and MPZ (MIM
*159440) that are linked to subtypes of Charcot-Marie-
Tooth (CMT) disease also demonstrate high relative ex-
pression levels in tibial nerve (Supplementary Fig. 1B and
C). Thus, although to date there have not been any human
disorders associated with this gene, VWA1 represents an
interesting candidate for peripheral nerve related
phenotypes.
In this study, a combination of genome, exome and tar-
geted sequencing approaches was used in tandem with inter-
national gene-matching and autozygosity mapping to
identify 15 families with biallelic variants in VWA1. RNA
analysis and a number of in silico tools were used to predict
the likely consequences of the variants uncovered whilst
Western blotting assessed mutational effects at the protein
level. Detailed clinical information for this cohort is
presented and for a subset of families, availability of genome
sequencing data facilitated a high-resolution haplotype ana-
lysis for individuals homozygous for the primary disease-
associated allele. Finally, the effect of defective Vwa1 on
axonal development and synapse formation was assessed in
zebrafish.
Materials and methods
Analysis of genome sequence data
within the GEL research
environment
For Families 1–10, genome sequencing was performed as part
of the 100K Genomes Project (100KGP), a national genome
sequencing initiative (Turnbull et al., 2018; Turro et al., 2020).
For the majority of cases, sequencing was performed using 150-
bp paired-reads on a HiSeqX instrument (Illumina). In this
study, we searched data from release v8 (2019-11-28) of the
100KGP, specifically looking for rare biallelic variants in
VWA1. Multiple filtering strategies were used, as described in
Supplementary material. Of the 10 families identified below,
five patients had been sequenced as singletons, four as parent-
child trios and one as a mother-child duo. Genomics England
has approval from the HRA Committee East of England,
Cambridge South (REC: 14/EE/1112).
Haplotype analysis in seven
individuals homozygous for
p.G25Rfs*74
Joint variant calling was performed across all seven individuals
homozygous for the p.G25Rfs*74 variant (Supplementary
material). For all high-confidence SNVs with a minor allele fre-
quency of 41%, we plotted information content (reciprocal of
1000 Genomes project allele frequency) versus genomic position
where single nucleotide polymorphisms (SNPs) were shared
homozygous in 7/7. For some individuals the ancestral haplo-
type extended further and so review of the multi-sample VCF
and the BAM files was performed using IGV to delineate precise
region lengths. The ancestral haplotype block sizes were used to
estimate the age of the p.G25Rfs*74 variant, as described previ-
ously (Gandolfo et al., 2014). For comparison, we performed
an identical analysis for 10 unrelated ataxia patients from the
100KGP, homozygous for the intronic AAGGG repeat expan-
sion in RFC1 (Cortese et al., 2019). These individuals had been
detected in using ExpansionHunter v2.5.5.
Structural analysis of VWA1
Structural analysis of VWA1 was calculated with PyRosetta
(Chaudhury et al., 2010) and results are presented via a web-
based application (Ferla et al., 2020) that promotes the sharing
of 3D macromolecular visualizations.
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Identification of families with VWA1
variants through international
gene-matching efforts
Identification of additional families with biallelic variants in
VWA1 was performed by using GeneMatcher (Sobreira et al.,
2015) and a network of established collaborators. For Family
11, exome sequencing was performed as a trio at GeneDx
(Gaithersburg, MD) as described (Retterer et al., 2016).
Variants were scrutinized using Xome Analyzer, a custom-devel-
oped analysis tool. The proband in Family 12 was exome
sequenced in the Nijmegen diagnostic laboratory as a singleton,
in collaboration with BGI Europe. Sequencing was on an
Illumina HiSeq instrument after exome enrichment with the
Agilent SureSelectXT Human All Exon 50Mb Kit.
Autozygosity analysis in an
extended kindred
For Family 13, exome enrichment was performed on the pro-
band and his uncle using the SureSelectXT Human All Exon
Kit V6 (Agilent Technologies). Sequencing was on an Illumina
NovaSeq instrument as paired-end 2  150-bp reads with
50 coverage. Genetic variants were identified using the
GATK suite v4.0.4.0 and the multi-sample vcf was uploaded
to www.homozygositymapper.org for analysis, with the re-
quirement for genetic homogeneity. Variants were also ana-
lysed using Ingenuity Variant AnalysisTM (Qiagen, Redwood
City). Given the known consanguinity in this family, we
focused on rare homozygous variants present in regions of
autozygosity shared between the proband and the uncle. A
more detailed description of variant filtering is available in the
Supplementary material.
Targeted sequencing of replication
cohort
Sanger sequencing was performed in two independent cohorts;
374 unrelated patients from UK with a range of complex per-
ipheral neuropathies and 967 unrelated patients suspected of
spinal muscular atrophy from Cologne. The latter cohort was
selected based on negative results upon SMN1 testing, with
patients 42 years of age when samples were received.
Polymerase chain reaction (PCR) was used to amplify exon 1 of
VWA1 using 85–100 ng of template DNA. Because of the
high GC content, Q5 high GC enhancer (BioLabs) or DMSO
(Applichem) was added for efficient amplification. Enzymatic
clean-up followed with a mixture of FastAPTM Thermosensitive
Alkaline Phosphatase and ExoI (Thermo Scientific or NEB).
Samples were either sent to SourceBioscience, Eurofins,
Microsynth or sequenced in house using BigDyeV
R
(Applied
Biosystems or Life Technologies). Following a SephadexTM G-
50 purification step, sequences were read by a 3500/3730 DNA
Analyzer and analysed using Sequencher (GeneCodes) or
SeqPilot (JSI Medical Systems).
Clinical data collection
A detailed clinical pro forma was circulated to all clinicians
from February 2020 onwards, along with requests for
neurophysiology data, muscle histology results, muscle MRI
data and any photos/videos where consent was forthcoming.
Written informed consent for genetic testing and photo materi-
als were obtained from the patients, parents or legal guardians.
The study was conducted in accordance with the Declaration
of Helsinki and approved by the relevant institutional review
boards.
Analysis of VWA1 transcript levels
Following informed consent (12-N-0095, NIH, NINDS IRB), a
skin biopsy was performed on the proband from Family 11 and
a dermal fibroblast cell line was established using a standard
protocol. Total RNA was isolated with the RNeasyV
R
mini Kit
(Qiagen) and reverse transcribed into cDNA with SuperScriptTM
IV reverse transcriptase (ThermoFisher Scientific). VWA1
transcript levels in patient fibroblasts were compared to that
in control fibroblasts using duplex PCR, with primers in
VWA1 (GAGCGAGCGAGCGAGTTG, GTCCAGCAGGAAC
ATCAGGT) and control primers targeting ACTB. To determine
if the 10-bp insertion causes nonsense-mediated decay, dermal
fibroblasts were treated with 0.2 mg/ml cycloheximide (CHX;
Sigma) for 19 h.
VWA1 abundance in cultured
dermal fibroblasts
Confluent cultures of dermal fibroblasts from the patient in
Family 11 and a healthy control were grown in serum free
medium for 40 h. Conditioned medium and cell layer were
then collected separately. Protein from the conditioned me-
dium was precipitated with cold ethanol and dissolved in 2
LDS buffer (ThermoFisher Scientific). The protein lysate from
the cell layer was prepared with 4 M guanidine hydrochloride
(GuHCl), as described (Allen et al., 2008). Aliquots of the
above lysates were analysed by western blot using 4–12%
SDS-PAGE under reducing conditions followed by transfer to
PVDF membrane (Millipore) and incubation with sheep anti-
body against VWA1 (Allen et al., 2008). Protein lysates pre-
pared from mouse nerve tissue and mouse nerve primary
culture were also loaded as positive controls. The same mem-
brane was also blotted with antibodies against fibronectin and
tubulin as loading controls.
Zebrafish vwa1 modelling
Zebrafish (Danio rerio) wild-type and transgenic
(Tg:olig2:dsRed) adults were maintained in standard conditions
under approved protocol by the local Animal Care (QU-IACUC
26-2/2018-REN1). Precision gene editing and transient knock-
down approaches targeted ENSDARG00000075468, the zebra-
fish orthologue of the human gene VWA1. Zebrafish vwa1-
specific guide RNAs were TGTAGAAGAGGTTAAACTGG
and CAGAACACAGAAACACGGTG. Morpholinos (MOs)
targeting the three protein-coding transcripts were MO:
50ACATGACCAAAACGACTCACCTGAA30-Blue and a
Standard Control MO: 50CCTCTTACCTCAGTTACAATTT
ATA30 (Gene Tools). Injections were performed as described
previously, with a final dose of 0.5 mM (Da’as et al., 2020).
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Motor neuron length measurements
Phenotypic assessment and imaging was performed on the
olig2-labelled elongated axons. Larvae were immobilized in 3%
methylcellulose (Sigma, M0387) for imaging. The motor axon





Immunofluorescence was performed as described (Sufian et al.,
2019). Fixed zebrafish groups were incubated overnight at 4C
in mouse monoclonal anti-znp1 or anti-zn8 (Developmental
Studies Hybridoma Bank) antibodies then incubated in the sec-
ondary antibody, Alexa FluorV
R
488 goat anti-mouse IgG over-
night at 4C. Phalloidin and alpha-bungarotoxin staining was
performed as described (Bailey et al., 2019). Samples were co-
stained in 1/20 phalloidin-488, which was added to the alpha-
bungarotoxin solution in PBS-2% TritonTM X-100 overnight at
4C.
Cartilage Alcian blue staining
Cartilage was stained via a modified version of established pro-
tocols (Delbaere et al., 2019; Gebuijs et al., 2019). Larvae were
fixed for 6 h in 4% paraformaldehyde. Specimens were
bleached for optical clarity in 1% hydrogen peroxide, 1% po-
tassium hydroxide and 0.2% Triton for 1 h. Staining with
Alcian blue was performed for 3 h and this was followed by a
clearing step in acidic ethanol (5% hydrochloric acid, 70% etha-
nol) for 10 min then transferred to pure glycerol for imaging.
Zebrafish locomotor behaviour
measurements
Tail flicking activity was assessed as described (Basnet et al.,
2017). Briefly, the spontaneous tail coiling was evaluated by
acquiring 20 s interval video recording for the embryos at
24 hours post fertilization (hpf). The video was obtained at
60 frames per second setting using Imaging Source camera.
Locomotion activity of embryos was evaluated by analysing
the acquired videos using DanioScope software (version 1.1,
Noldus, The Netherlands). Each embryo was selected by
drawing a separate arena around its chorion to detect the
movement of the tail. The locomotion activity was measured
for 10–20 embryos, and the results were compared to the
control groups.
Zebrafish larvae locomotor activity was monitored at 120 hpf
using an automated Video-Track system (Noldus, Ethovision
XT), as described (Basnet et al., 2019). Larvae were placed
individually in a six-well plate. Larval swimming behaviour was
monitored in response to dark-to-light transitions. The loco-
motor behaviour was monitored, and the collected data were
analysed using Ethovision XT software.
Data availability
Information about how to access data from the 100KGP by
joining a Genomics England Clinical Interpretation Partnership
(GeCIP) is available online (www.genomicsengland.co.uk/join-a-
gecip-domain).
Results
Biallelic VWA1 variants in the 100K
Genomes project
We searched data from the 100KGP (Turnbull et al., 2018)
for families where affected individuals harboured biallelic
variants in VWA1. Ten families of interest were uncovered,
all of which harboured a 10-bp insertion (c.62_71dup10;
p.G25Rfs*74, NM_022834.5). In seven families, this variant
was observed in the homozygous state in affected individu-
als, whereas in the other three families the p.G25Rfs*74 al-
lele was heterozygous alongside a rare heterozygous SNV
(Fig. 1A). Two of these SNVs predict missense alterations
(p.S74R and p.Y364N) in functional protein domains
involving conserved residues (Fig. 1B and C) whilst the other
predicts a stop-gain (p.Q367*). The p.Ser74 residue has
previously been shown to undergo phosphorylation
(Tagliabracci et al., 2015). Structural analysis suggests that
p.S74R and p.Y364N are both likely to destabilize VWA1,
with DDG values of +24 and +10 kcal/mol, respectively
(interactive view: https://michelanglo.sgc.ox.ac.uk/r/vwa1), a
higher predicted change in Gibbs free energy than obtained
for the six homozygous missense variants observed in
gnomAD. Other in silico predictions for these variants are
available in Supplementary Table 1.
For Families 3 and 8, affected individuals were genome
sequenced as singletons. As both individuals are 470
years old, parental samples were not available to establish
the phase of the variants. For Family 3, allele-specific PCR
was used to confirm that the p.G25Rfs*74 and p.S74R
variants lay in trans (Supplementary Fig. 2). For Family 8,
the two variants lay 3.75 kb apart. Nanopore sequencing
on the affected individual, resulted in a genome-wide
coverage of 13 and a mean aligned read-length of
16 017 bp. These data suggested that p.G25Rfs*74 and
p.Q367* were oriented in trans (Supplementary Fig. 3). In
Family 10, compound-heterozygosity of p.G25Rfs*74 and
p.Y364N was already established as both parents had
been sequenced in parallel. These 10 unrelated patients
from the 100KGP had been recruited under four related
diagnostic categories, the most common being CMT dis-
ease and paediatric motor neuronopathies, where 0.85/
0.86% cases were identified with biallelic VWA1 variants
(Table 1).
Haplotype analysis suggests
p.G25Rfs*74 is an ancient European
founder mutation
Expansions of repetitive stretches of DNA are considered to
be one of the more recurrent forms of genetic variation.
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Figure 1 Pedigrees, variant localization and evolutionary conservation of missense changes in VWA1. (A) Pedigrees of the 15 fami-
lies described here with predicted protein consequences of variants and the segregations pattern, where known. NA = DNA not available for
testing. Filled symbols indicate early onset motor axonal neuropathy. Grey shading in Family 11 indicates a neurological presentation consistent
with the observed duplication of 16p13.2. Genotype in younger twin in Family 12 was inferred because of monozygosity. (B) Schematic diagram
showing the position of the variants identified in this study in relation to the protein domains in VWA1. The VWFA domain is shown in green
whilst the two fibronectin type-III domains are shown in black. Figure is based on coordinates as listed in entry Q6PCB0 of the UniProt database
(www.uniprot.org). (C) Evolutionary conservation of amino-acids in VWA1 orthologues at p.Ser74 and p.Asn364, the two sites where missense
changes were identified.
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However, the 10-bp repeat in exon 1 of VWA1 only has
two copies in the reference and the expansion to three copies
(p.G25Rfs*74) appears to be a relatively stable founder mu-
tation. Of the 89/140 632 expanded (3  10 bp) alleles seen
in gnomAD v3, all are in a heterozygous state and the ma-
jority (58/89) are in individuals with non-Finnish European
ancestry. Haplotype analysis performed on the seven homo-
zygous individuals where genome sequence data were avail-
able identified a shared haplotype of 220.4 kb that extends
mainly in the distal direction. For the most informative
SNPs on this haplotype, the alternate alleles (rs114330234-
rs78379068-rs76947392-rs188670510-rs144707149; T-T-
A-T-T) are observed at 1.2–3.9% in the 1000 Genomes pro-
ject (Fig. 2). The three compound heterozygous individuals
(Families 3, 8 and 10) are also heterozygous for this set of
alleles. The small size of this shared ancestral haplotype
makes it unlikely that the VWA1 founder mutation is from
a recent common ancestor (Speed and Balding, 2015).
Further refinement of the founder haplotype showed that for
some patients the region extended up to 471.5 kb
(Supplementary Table 2). Using a previously described
method (Gandolfo et al., 2014), we estimated this mutation
to be 311 generations old (95% confidence interval:
107–975; Supplementary Table 3). Assuming an average of
25 years per generation, this equates to 7775 years
(Supplementary Table 4). These haplotype data may be use-
ful in prioritizing European neuropathy patients for targeted
VWA1 sequencing, for instance rs78379068 is genotyped on
Illumina’s Infinium Global Diversity Array. For comparison,
we assessed 100KGP data for 10 individuals homozygous
for the AAGGG insertion in RFC1, also a known disease-
causing repeat expansion and present in Europeans at an al-
lele frequency of 0.7% (Cortese et al., 2019). An ancestral
haplotype of 58.2 kb was seen across all individuals (Fig. 2),
suggesting that this variant is likely to be older than the
VWA1 founder mutation.




A further five affected individuals from three independent
families were identified (Fig. 1A) by exome sequencing.
Similar to Families 1–10, Families 11 and 12 are both small
outbred kindreds of European ethnicity where affected indi-
viduals harboured the homozygous p.G25Rfs*74 founder
variant. In contrast, Family 13 is of Afghan origin and the
only family in which consanguinity was documented.
Retrospective homozygosity mapping detected a 1.5 Mb re-
gion spanning VWA1 (chr1:137825–1646565 GRCh38/
hg38) comprising 11 consecutive homozygous SNPs as the
joint second highest scoring region (Supplementary Fig. 4
and Supplementary Table 5). The only larger regions
detected were on chromosomes 3 and 7. In the proband’s
exome, 712 rare (0.5% or less) deleterious variants were
identified, of which 80 were called homozygous. Filtering
these variants for those in shared autozygous regions identi-
fied c.462delC; p.M155Cfs51 in VWA1 as the only candi-
date variant.
Genetic replication via targeted
sequencing
In an attempt to replicate the results obtained from genome/
exome sequencing, 1341 DNA samples from two
independent cohorts of patients (374 from UK, 967 from
Germany) with unsolved neuropathies were tested for the
p.G25Rfs*74 founder mutation by screening exon 1 using a
Sanger sequencing approach. This yielded three additional
diagnoses: (i) an 83-year-old male with suspected non-length
dependent hereditary motor neuropathy who harboured the
Table 1 Incidence of VWA1 cases with biallelic variants identified in the 100K GP across different diagnostic
categories
Disease subgroup Specific disease Biallelic VWA1 cases Participant counta Frequency
Motor and sensory disorders of the
peripheral nervous system
Charcot-Marie-Tooth disease 6b 708 0.85%c
Paediatric motor neuronopathies 1 116 0.86%
Neuromuscular disorders Congenital myopathy 2 479 0.42%
Limb girdle muscular dystrophy 1 253 0.40%
Above diseases combined 10 1556 0.64%
All 100KGP participants with specific disease 10 40 088 0.02%
All 100KGP participantsd 10 74 180 0.01%
aNumbers based on CohortBrowser v8 (28 November 2019).
bContains one case with p.[G25Rfs*74];[S74R] phased by allele-specific PCR, one case with p.[G25Rfs*74];[Q367*] phased by Nanopore sequencing and one case with
p.[G25Rfs*74];[Y364N] phased by inheritance.
cThis frequency rises to 1.12% (6/535) if the denominator is recalculated considering only the proband in each family and removing individuals where ethnicity is reported as Black,
Asian, Chinese or ‘other’.
dIncludes unaffected family members.
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homozygous p.G25Rfs*74 variant; (ii) a 24-year-old female
with distal axonal motor neuropathy who was compound
heterozygous for p.G25Rfs*74 and p.R293Sfs*58 (Fig. 1A)
and (iii) a compound heterozygous individual (p.G25Rfs*74
and p.R32*) who is described elsewhere (Deschauer et al.,
2020) and so detailed phenotypic information is not
presented.
Phenotype range associated with
biallelic VWA1 variants
Clinical data were assembled from 17 affected individuals
across 15 independent families, all shown to carry biallelic
VWA1 variants (Table 2, Supplementary Table 6 and
Supplementary material, case reports). Videos are available
for affected probands in Families 1, 3, 8, 10–13 and 15
(Supplementary Videos 1–8) and additional clinical images
are shown for the proband from Family 13 (Supplementary
Fig. 5). Although there was a wide age range (6–83 years),
children made up 35% of this series. Positive family history
was reported only in Family 13, while the rest of the cases
were sporadic. The common disease presentation in the
cohort was an early-onset slowly progressive non-length de-
pendent predominantly axonal motor neuropathy, often
with early distal weakness and foot deformities progressing
over the years to involve proximal muscle groups.
The mean age of symptom recognition was 2.0± 1.4 years
with tip-toe walking, foot deformities, Achilles tendon con-
tractures, and recurrent hip and patellar dislocations.
Independent walking in the cohort was achieved by the
mean age of 1.6± 0.8 years and it was remarkably delayed
in cases with foot deformities such as severe bilateral equino-
varus (18%, 3/17). In two independent cases, the foot
deformities and tendon contractures were congenital suggest-
ing antenatal onset of the disease. The aforementioned pre-
senting symptoms in the cohort were typically followed by
the development of slowly progressive symmetric distal and/
or proximal muscle weakness in the lower limbs. In over
half of the affected individuals, weakness spread to the
upper limbs over time predominantly affecting the proximal
muscles.
Most of the cases (75%) were found to have simultaneous
proximal and distal lower limb weakness on neurological
follow-up. In almost half of those cases, weakness was more
Figure 2 Haplotype analysis performed on individuals with homozygous repeat expansions in VWA1 (top) compared to similar
results for RFC1 (bottom). Shared homozygous SNPs are plotted for 20 Mb segments of chromosome 1 and 4. In both cases, the most signifi-
cant regions detected span the VWA1 and RFC1 loci where several consecutive SNPs are homozygous in 7/7 or 10/10 individuals respectively. For
the VWA1 locus, the five shared SNPs labelled with rsIDs are highly informative, with global 1000 Genomes project allele frequencies 55%
(1000G AF). The reciprocal of the allele frequency is plotted on the y-axis to give an idea of the information content for each of the shared SNPs.
Within the VWA1 haplotype block we also observed a rare SNV in the 50-UTR of ANKRD65 (rs758603246), which is heterozygous in 3/7 individu-
als. The variants appear to be in complete linkage disequilibrium as in the 100KGP all individuals with rs758603246 also have p.G25Rfs*74. Our
interpretation is that rs758603246 is a more recent mutation and so is observed only on a subset of p.G25Rfs*74-containing haplotypes.
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pronounced proximally, and one-quarter had equally weak
proximal and distal muscle groups, raising the clinical suspi-
cion of non-length dependent motor axonal neuropathy.
Weakness was mild in the upper limbs, and ranged from
mild to near-complete paralysis in the proximal and distal
lower limbs, irrespective of age.
Bilateral foot drop, impaired toe walking, forward pos-
ture, and wasting in the lower limbs were frequently
observed signs. Of note, bilateral foot deformity was a
very frequent feature revealed in almost 90% of the cases
(15/17), ranging from pes cavus (65%, 11/17) to talipes
equinovarus (35%, 6/17). Less frequent but present in
more than half of the cohort were flexion tendon contrac-
tures typically involving foot plantar flexion, knee, and hip
flexion but in some cases, it was also present in the major
joints of the upper limbs. Scoliosis and lumbar hyperlordo-
sis were present in half of the series. One-third of the cases
experienced frequent falls but despite the long disease
course (median disease duration 36.5 years), only three
members of the cohort (twins from Family 12 and index
case from Family 6) had lost independent ambulation.
Three isolated cases had an abnormal sensory examination
and this was supported by neurophysiological evidence in
only one of them showing asymmetrical sural nerve in-
volvement (Family 6). Tendon reflexes were diminished in
half of the cohort, and muscle tone was largely reported to
be normal along with uniformly negative Babinski sign.
Two adult cases (Families 1 and 3) had shown mild tongue
fasciculations or atrophy.
Based on the presence of proximal muscle weakness in the
upper and lower limbs associated with myalgia, myopathic
gait, and scapular winging, several cases were suspected to
have additional clinical signs suggestive of myopathy. In six
affected individuals, creatine kinase levels were elevated
(369–1628 IU/l).
The homozygous carriers of p.(G25Rfs*74) largely showed
a comparable pattern of neuromuscular and associated symp-
toms. Cases with compound heterozygous VWA1 variants
p.(G25Rfs*74); p.(S74R) and p.(G25Rfs*74); p.(Q367*),
both 470 years old, as well as the 24-year-old with
p.[G25Rfs*74];[R293Sfs*58] seemed to present with a
milder phenotype. Overall, the disease progression was very
slow or even static in several cases. Isolated cases reported
some clinical worsening after the fifth decade of life.
Available nerve conduction studies typically revealed
findings consistent with a motor axonal neuropathy which
was often interpreted as suggestive of a distal spinal mus-
cular atrophy/hereditary motor neuropathy. Motor nerve
action potentials from the lower limb nerves were reduced
or undetectable with uniformly preserved conduction
velocities. Sensory studies were overall normal. EMG typ-
ically showed chronic neurogenic changes without active
denervation (10/12). Three EMG studies were reported to
suggest myopathic features, albeit for two of them the for-
mal report was unavailable. Table 3 displays the nerve
conduction studies and EMG parameters from the formal
reports available.
Muscle biopsies were performed in seven cases, of which
four were available for review (Fig. 3). In 4/7 of these, clear
neurogenic changes were reported. In the other three
Table 2 Summary of clinical features in the VWA1 cohort
Clinical feature/demographic
Number of individuals n = 17
Ethnicity
White British 6 (35%)
Mixed British 3 (18%)
Caucasian non-British 4 (23%)
Afghan 2 (12%)
Unknown 2 (12%)
Gender 11 males/6 females
Family history (of NMDs) 3 (18%)
Consanguinity 2 (12%)
Current age Median 42
Current age 511 years 6 (35%)
Age of symptom recognition, years Mean 2.0± 1.4
Disease duration Median 36.5
Age at examination Median 37.5
Age of independent walking Mean 1.6 ± 0.8 (12)
Slow disease progression 17 (100%)
Joint flexion contractures 9 (53%)
Spinal deformities (Scoliosis, lumbar hyperlordosis) 8 (47%)
Foot deformities 15 (88%)
Pes cavus 11 (65%)
Talipes equinovarus 6 (35%)
Foot surgery 3 (18%)
Myalgia 7 (41%)
Frequent falls 6 (35%)
Forward stood posture 6 (35%)
Loss of independent ambulation 3 (18%)
Tongue fasciculations or atrophy 2 (12%)
Scapular winging 2 (12%)
Lower limb weakness
Weakness in the proximal muscle groups 13/16 (81%)
Weakness in the distal muscle groups 15/16 (94%)
Only distal weakness 3/16 (19%)
Only proximal weakness 1/16 (6%)
Simultaneous proximal and distal weakness 12/16 (75%)
Proximal 4 distal weakness 5/12 (42%)
Distal 4 proximal weakness 4/12 (33%)
Proximal = distal weakness 3/12 (25%)
Foot drop 9 (53%)
Impaired toe walking 6/13 (46%)
Lower limb amyotrophy 10 (59%)
Upper limb involvement 11 (65%)
Upper limb weakness
Proximal muscle groups 10 (59%)
Distal muscle groups 8 (47%)




Myopathic gait 6 (35%)
Motor axonal neuropathy on NCS 15/15 (100%)
Myogenic changes on EMG 3/12 (25%)
Denominator is 17 unless otherwise stated. NCS = nerve conduction studies;
NMDs = neuromuscular disorders.
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biopsies there was evidence for myopathic features in add-
ition to findings suggestive of an underlying neurogenic pro-
cess. Where data were available, immunohistochemical
labelling for collagen VI appeared normal.
Muscle MRIs were available in four cases, of which three
were available for review. This displayed increased signal in-
tensity or fatty replacement predominantly in the vastus
lateralis and anterior compartment of the lower legs on
T1-weighted sequences suggesting chronic denervation
(Supplementary Fig. 6). In one affected individual a muscle
MRI was interpreted as compatible with a myopathic condi-
tion; however, the MRI images from this case were not avail-
able for review.
Transcripts harbouring founder
mutation are partially degraded by
nonsense-mediated decay in
fibroblasts
The major disease-associated insertion allele results in a
frameshift and the introduction of a premature stop signal 74
codons downstream. Mutant transcripts would therefore be
predicted to be subject to nonsense-mediated decay. To test
this possibility, duplex reverse transcription polymerase chain
reaction (RT-PCR) was performed using RNA from dermal
fibroblasts obtained from the proband in Family 11. VWA1
transcript levels were reduced compared to two controls. The
VWA1/ACTB ratio was partially restored when patient fibro-
blasts were grown in presence of cycloheximide (Fig. 4A) sug-
gesting that the 10 bp insertion results in transcripts that are
partially degraded by nonsense-mediated decay.
No detectable VWA1 protein in
patient fibroblasts
Detectable levels of VWA1 were seen in dermal fibroblasts
from a healthy control. Although secreted VWA1 was not
able to incorporate into ECM (cell layer), it was detectable
in the conditioned medium. However, there was no detect-
able VWA1 in either the conditioned medium or cell layer of
the patient’s fibroblast (Fig. 4B). A high level of VWA1 was
detected in mouse sciatic nerve extraction. In the primary
culture of mouse sciatic nerve, VWA1 was detectable in its
cell layer (cytoplasm and ECM) but not in the conditioned
medium, indicating the secreted VWA1 was able to deposit
as ECM efficiently.
Zebrafish vwa1 model leads to
motor neuron malformations
The zebrafish Vwa1 protein shares 64.7% similarity across
a 408 amino acid overlap with human VWA1. Zebrafish
were successfully injected with gene-specific CRISPR and an
antisense morpholino targeting the vwa1 protein-coding
transcripts exon 1–2, which contained a blue-emitting fluor-
escent tag at the 30 end (Supplementary Fig. 7A).
Investigation of the effect of different concentrations of
vwa1 MO showed a dose-dependent phenotypic severity
indicating the specificity of vwa1 knockdown. The altered
splicing had a negative effect on survival rate compared to
controls. For both models, the examined groups’ gross
morphology was comparable to the control group
(Supplementary Fig. 7B).
Phenotypic assessment of the vwa1 crispants/morphants
demonstrated a prominent effect on motor neurons includ-
ing shorter axons and abnormal growth. Aberrant axon
structures were observed from Day 3 and there was a signifi-
cant reduction in spinal motor neuron growth measured
through development at Days 2–4 (Fig. 5). It was observed
that vwa1 knockdown/knockout caused apparent develop-
mental deformities in developing motor neurons
(Supplementary Fig. 8). The examined primary motor neu-
rons showed reduced axonal branching innervating the
muscle fibres and aberrant secondary motor neurons with










































F1 50 6.8 55.4 ND ND ND ND 0.53 38 10.2 69.3 5.2 64.7 ND ND 6.7 59.6 +
F4 8 ND ND ND ND UD UD 2.2 41 ND ND ND ND ND ND 8.6 50 17.7 54 +
F6 40 24.5 56.8 ND ND UD UD ND ND ND ND ND ND 60.1 54.9 7.30 41.7 5.2 36.6 
F8 70 7.7 59.1 7.3 62.5 3.6 54 1.1 50 21 57.4 10 59.9 ND ND 33 68.2 18 47.3 +
F11 8 2.7 48 4.6 55 0.5 48 0.8 46 ND ND ND ND 23.9 54 16.3 48 ND
F12a 57 7.1 51.6 7.2 55 UD UD 2.7 33.9 ND ND ND ND 20.5 53.3 6.2 38.4 +
F13b 8 5.9 49 4.6 54 0.2 41 2.7 47 18.2 53 15.4 54 ND ND 7.2 66 11 47 ++
F15 24 ND ND 17.3 66 4.3 44 13.5 48 ND ND 34 53 ND ND 19.1 43 ND ND +
Nerve conduction study parameters are those from the right limbs. Amp = amplitude; CV = conduction velocity (m/s); LL = lower limbs; ND = not done; UD = undetectable
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Figure 3 Muscle biopsy images from our patients all homozygous for p.G25Rfs*74. (A) Muscle biopsy (quadriceps) from a patient in
Family 2 (performed at age 41 years). Images show marked fibre hypertrophy and increased fibrosis with endo and perimysial fatty infiltration.
Labelling for collagen VI appears normal. (B) Muscle biopsy (right quadriceps) from a Family 4 patient (aged 6 years). Biopsy shows predominant-
ly neuropathic aspects with neurogenic atrophy (arrow) and thickening of the endomysium and perimysium. Fascicular grouping of type 1 fibres
implicates a chronic neurogenic process. NADH-TR shows the presence of moth-eaten fibres (non-specific finding). (C) Muscle biopsy (quadri-
ceps) from a patient from Family 5 (aged 41 years). Marked variation in fibres size and increased endomysial fibrosis with mostly perimysial fatty
infiltration. Rimmed vacuoles are shown with an arrow. There is a large predominance of type 2 fibres. Labelling for collagen VI appears normal.
(D) Muscle biopsy from the index case in Family 12 (right vastus lateralis, age 52). Myopathic features are present, with marked fibre lobulation
and variable degree of whorling of myofibrils (arrow). Endomysial fatty infiltration. Large areas of fibre grouping in this biopsy as well indicates a
neurogenic aetiology. ATPase staining was performed at pH 4.2. H&E = haematoxylin and eosin.
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severe defects in the middle and caudal axons of secondary
motor neurons with some early truncation of these axons.
The skeletal muscle structure was evaluated in develop-
ing somites using phalloidin stain for filamentous actin (F-
actin). Control groups displayed densely packed and
organized muscle fibres, while the zebrafish vwa1 model
revealed sparser fibre arrangement, with the appearance of
some disorganized myofibres. Moreover, examination of
neuromuscular junctions, by targeting the acetylcholine
receptors (AChR) using alpha-bungarotoxin stain, revealed
significantly reduced synaptic formation in the skeletal
muscles (Supplementary Fig. 9). These results established
that vwa1 is required for the proper organization of skel-
etal muscles and in the formation of neuromuscular
junctions.
Additionally, the gross morphological appearance of
vwa1 crispants/morphants displayed a different cartilage
patterning. Zebrafish vwa1 also appears to be required for
jaw joint development and helped pattern the ventral
cartilage. The structure and area of the arches Meckel’s
and palatoquadrate were irregular in the vwa1 model
(Supplementary Fig. 10A). The size of the jaw from the
Meckel’s to the interhyal structure was also significantly
reduced (Supplementary Fig. 10B).
Finally, locomotor behaviour was assessed in the zebrafish
CRISPR vwa1 knockout model. The model exhibited no im-
pact at the first neuronal motor spontaneous movements at 1
day old (Supplementary Fig. 11). However, a consistent trend
developed at 5 days old towards: (i) reduced total distance
moved over time; (ii) reduced velocity; and (iii) increased fre-
quency of non-movements from centre point when compared
to control group (Supplementary Fig. 12A–C).
Discussion
Over the past decade, availability of next-generation
sequencing data for large patient cohorts has facilitated the
discovery of numerous genes responsible for Mendelian dis-
orders. It is likely that most of the ‘low-hanging fruit’ has
been gathered already and in the future, discovery of novel
monogenic disease entities will be limited to increasingly
rare conditions, to syndromes where the causative variant is
non-coding or where complex rearrangements that are diffi-
cult to detect with short-read technologies are involved. In
this study, using data from the 100KGP, through inter-
national collaboration and by targeted sequencing, 17 indi-
viduals from 15 families harbouring biallelic variants in
VWA1 were identified.
The major disease-associated allele in VWA1 involves an
insertion of GGCGCGGAGC at the end of exon 1.
According to the global allele frequency in gnomAD v3, the
high frequency of this founder mutation (89/140 632) is
comparable with other well-known variants seen in related
autosomal-recessive conditions (Supplementary Table 7),
coming just after the recently described p.A253Qfs*27 in
SORD (623/142 588), p.I41T in FIG4 (164/143 266) and
p.R954* in SH3TC2 (94/143 270). In European popula-
tions, the allele frequency of p.G25Rfs*74 rises to almost 1/
1000. The 0.091% (58/63 526) allele frequency reported in
gnomAD for non-Finnish Europeans is in line with the
0.087% (188/215 908) in the GeneDx exome database, the
0.094% (112/118 908) seen in the 100KGP project
Figure 4 Consequences of the 10 bp insertion at the tran-
script and protein level. (A) Duplex PCR suggests a 10 bp inser-
tion results in partial nonsense-mediated decay. RT-PCR products
using primers for VWA1 and ACTB using RNA from proband in
Family 11 (P) compared to control fibroblasts (C2, C2). The ratio of
VWA1 to ACTB was reduced in the patient but was restored when
patient fibroblasts were grown in presence of the nonsense-medi-
ated decay inhibitor cycloheximide (CHX). (B) Immunoblotting indi-
cated detectable levels of VWA1 (WARP) in human healthy control
dermal fibroblasts; although the secreted VWA1 was not able to
incorporated into ECM (cell layer), it was detectable in the condi-
tioned medium. In contrast, no detectable VWA1 was seen in the
patient’s dermal fibroblast in either the conditioned medium or the
cell layer. A high level of VWA1 was detected in mouse sciatic nerve
extraction (m-nerve). In the primary culture of mouse sciatic nerve
(mnf), the VWA1 was detectable in its cell layer (cytoplasm and
ECM) but not in the conditioned medium, indicating the secreted
VWA1 was efficiently deposited as ECM. Tubulin and fibronectin
(FN) used as loading controls. GuCHL = guanidine hydrochloride
extraction.
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Figure 5 The vwa1 zebrafish model has impaired spinal motor neuron axon development. Transgenic embryos [Tg(olig2:dsRed),
expressing red fluorescent oligodendrocytes and motor neurons axons) were injected with vwa1 CRISPR (knockout) or morpholino (MO,
knockdown). Both vwa1 models displayed a significantly shorter motor axons in comparison to control axon growth. Representative embryos
full-body lateral view and trunk lateral view for the examined groups at: (A) Spinal cord motor neurons examined at 48 hpf [enlarged images
below showing the measurement of axon length from the base of the spinal cord to the end of the motor neuron (white arrow)]; (B) 72 hpf,
examined spinal motor neurons (white box) and aberrant developing axons (white arrowheads); and (C) 96 hpf. (D) The vwa1 model resulted in
impaired motor neurons axon growth in comparison to control axon growth. Spinal motor neurons axon length was measured for 8–10 axons
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(Supplementary material and Supplementary Table 1) and
the 0.102% (82/80 048, all heterozygous) in UK Biobank
Exome sequencing data (https://pdgenetics.shinyapps.io/
VariantBrowser), consistent with the variant being wide-
spread in Europeans. Given this consistent allele frequency
and the support from the WARP mouse model published
over 10 years ago (Allen et al., 2009), we were initially sur-
prised that this disease gene had evaded discovery until now.
The reasons for this seems to be primarily of a technical na-
ture due to high GC content in VWA1 (Supplementary ma-
terial). Inefficient capture of this locus is observed in exome
sequencing, the methodology most widely used for many
clinical diagnostic laboratories, but this is less problematic
for whole genome sequencing methods (Supplementary Fig.
13). The p.A253Qfs*27 in SORD was also previously over-
looked likely due to technical reasons, although in that case
it was likely due to a highly homologous pseudogene
(Cortese et al., 2020).
Patient enrolment to the 100KGP spanned 4200 different
recruitment categories (Turnbull et al., 2018). Hereditary
motor neuropathy was not present in this list of available
options and the highest number of VWA1-positive cases was
instead seen in the CMT group, for an incidence of 0.85%
(6/708; Table 1). Revising the dominator to consider only a
single affected individual per family and removing individu-
als of non-Caucasian ethnicity, the incidence rises to 1.12%
(6/535). The lower frequency observed in the replication co-
hort (3/1341) may reflect differences in the ethnic back-
ground of the latter cohort (largely of German origin) and
the degree to which prior genetic testing had excluded
known neuropathy genes.
The uniform coverage afforded by the genome sequence
data available for a subset of families allowed us to perform
high-resolution analysis of haplotype sharing in individuals.
These results confirmed p.G25Rfs*74 to be a founder muta-
tion that may have arisen 47000 years ago. In tandem with
the uniform coverage across VWA1, our study highlights the
advantages of genome sequencing over exome sequencing
approaches.
Historically, the identification of novel autosomal-recessive
disease genes has often come from linkage-analysis and gen-
etic co-segregation in large, often consanguineous families.
In contrast, the majority of families in the present study are
singletons and thus support for pathogenesis is required
from different sources. Increasing availability of large stand-
ardized clinical genome datasets has meant that novel dis-
ease genes can be identified by looking for enrichment of
severe biallelic alleles above expectation and for phenotypic
similarity between patients harbouring putatively damaging
variants in the same candidate gene. For instance, the
Deciphering Developmental Disorders (DDD) study identi-
fied four novel recessive genes by performing formal statis-
tical assessment across all genes for the likelihood of
sampling the observed genotypes and combined this with
detailed analysis of Human Phenotype Ontology (HPO)
terms (Akawi et al., 2015). Although the VWA1 patients
from the 100KGP were identified by a straightforward can-
didate gene analysis following sharing of preliminary results
from Family 11, enrichment of homozygosity above expect-
ation and the phenotypic similarity of patients retrospective-
ly lends support to the p.G25Rfs*74 variant playing a role
in pathogenesis. Given the estimated allele frequency in
Europeans of 51/1000, the observation of the founder vari-
ant in seven homozygous individuals within the 100KGP
would be unlikely under the null-hypothesis. Our unbiased
analysis across the 100KGP was also significant in terms of
the phenotypic similarity seen in the identified patients. The
100KGP recruited across several rare disease areas, of which
peripheral neuropathies were just one component (Table 1).
It is therefore notable that our systematic analysis did not
detect any severe biallelic VWA1 variants in other disease
categories.
When a novel disease gene is implicated through a single
founder mutation, there is always a concern that there may
be an unobserved pathogenic variant on the same haplotype
(MacArthur et al., 2014). The coverage uniformity of gen-
ome sequencing means unobserved variants are less likely
than would be the case through exome sequencing, but still
does not 100% rule out that a detected variant has been
overlooked. It is therefore reassuring that we identified three
other variants predicted to result in premature termination
codons. The p.M155Cfs*51 variant lies in the VWFA do-
main and is supported by co-segregation (Fig. 1A and B). In
contrast, p.R293Sfs*58 and p.Q367* lie in the first and se-
cond fibronectin type III domains respectively and were iden-
tified in single affected individuals. For the latter two
variants, even if the truncated protein is stable, 153/423 or
79/423 of the wild-type amino acid sequence would be miss-
ing once the 22-amino acid signal sequence is removed
(Fig. 1B). Together with the immunoblotting results pre-
sented here (Fig. 4B), the absence of homozygous loss of
function alleles in gnomAD and the results from the knock-
out mouse model, where the mutant allele comprised a tar-
geted gene replacement (Allen et al., 2008), these set of
variants argues in favour of a loss of function disease mech-
anism. We note that functional studies would be required to
confirm pathogenicity for p.S74R and p.Y364N alleles
(Supplementary Table 1) and to support our structural mod-
elling results which suggest both substitutions to be
destabilizing.
Figure 5 Continued
per embryo starting from axon number 5. Vwa1 Crispants (n = 29) and morphants (n = 26) showed significantly shortened axons compared to
controls (n = 22). Zebrafish imaging using Lumar 12 microscope (whole body images, scale bar = 40 mm and axon images, scale bar = 10 mm),
t-test was used for statistical analysis. Spinal motor neuron images at a magnification of 150, scale bar = 10 mm. Statistical analysis was per-
formed with GraphPad Prism 8.0.
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Like many genomic resources, certain global ethnic catego-
ries are under-represented in data from 100KGP and
gnomAD. We were therefore interested to note that in the
internal CentoMDV
R
database (Trujillano et al., 2017), the
reciprocal 10 bp deletion (c.62_71del10) was present at an
allele frequency of 71/136 000 (mostly in individuals of
Middle Eastern ancestry) and so more common than
c.62_71dup10 (26/136 000). Although no biallelic cases
were identified, this shorter allele also predicts a premature
stop codon (p.G21Afs*12) and so we speculate this may
represent a second disease-causing founder mutation at the
same locus.
The common clinical denominator in the presented series
appears to be an early-onset slowly progressive non-length-
dependent hereditary motor neuropathy. Albeit the distal
presentation with foot deformities and distal weakness, the
progression to the proximal muscle groups, which in some
cases is more prominent than distal, raised in many instances
the suspicion of non-length dependent neuropathy. Impaired
nociception observed in WARP-null mice was not frequently
seen in the WARP-deficient individuals from this series.
A subset of paediatric cases in our cohort with only distal
lower limb weakness, wasting, and foot contractures
resembled the typical distal hereditary motor neuropathy
type I presentation (Garg et al., 2017). Although, with
advancing age, weakness in the present series tended to pro-
gress proximally. There was some degree of overlap with
spinal muscular atrophy with lower extremity predominance
caused by variants in DYNC1H and BICD2. Specifically,
the weakness that commenced and remained predominant in
the lower limbs affecting the proximal more than distal
muscles, character of the tendon contractures, foot and spi-
nal deformities, and forward stood posture (Rossor et al.,
2015; Scoto et al., 2015). However, in our series, the upper
limbs were involved in more than half of the cases irrespect-
ive of the disease severity, unlike spinal muscular atrophy
with lower extremity predominance.
Most of the EMG and over half of the muscle histology
studies evidenced clear neurogenic changes. Hence, neuro-
genic muscle changes seem to be common in the VWA1
presentation, and it is likely for the observed myopathic
process in a few cases to develop on the background of
chronic muscle denervation. Of note, all of the histological
features classically attributed to myopathy were abundant-
ly found in the chronically denervated muscles from the
poliomyelitis patients (Drachman et al., 1967). It has been
shown that myopathic changes may coexist with the clas-
sical pattern of denervation atrophy or dominated the bi-
opsy picture. Similar to our study, several cases from
DYNC1H and BICD2 gene-positive cohorts revealed myo-
pathic muscle biopsies (Rossor et al., 2015; Scoto et al.,
2015).
WARP and collagen VI are co-expressed in the endomy-
sium surrounding muscle fibres. However, WARP-null mice
showed that WARP does not have a critical role in stabiliz-
ing the ECM localization of collagen VI in muscle as
WARP-deficient mice expressed no histological or
behavioural evidence of muscle pathology (Allen et al.,
2009). Consistent with this, immunostaining muscle biopsies
of VWA1 patients for collagen VI appeared normal in our
study. Overall, the clinical and functional evidence from this
study has shown that WARP deficiency in humans is likely
to result in a non-length dependent motor axonal neur-
opathy. Characterization of further cases with WARP defi-
ciency will improve our understanding of the phenotype
range associated with this condition.
Comparative genome analysis has shown that 480% of
human genes linked to human monogenic disease have an
orthologue in zebrafish (Howe et al., 2013). Together with
the short generation time, high levels of fecundity, rapidly
developing transparent embryos and ease of manipulation
with MO technology, the zebrafish has become a powerful
model organism for studying vertebrate developmental
biology (Veldman and Lin, 2008). In this study we demon-
strated that defective vwa1 leads to subtle changes in
motor axonal growth/density at very early stages of devel-
opment (48–96 hpf) that correspond to the early stages of
human neuronal development. Indeed, recent papers high-
light the embryonic origin of many neuropathies and this
may potentially explain the involvement of VWA1 in the
CNS malformations associated with 1p36 deletion syn-
drome (Shiba et al., 2013). Zebrafish results were also
consistent with the mouse model, with its impaired fine
motor coordination (Allen et al., 2009) and the relatively
mild neuropathy seen in human patients described here.
Overall, the defective myofibres’ organization, neuromus-
cular junctions, secondary motor neuron impairment and
reduced larval locomotion may reflect the early vwa1
neuropathy. These observations encompass the specific de-
generation of developing motor neurons leading to muscle
weakness. The decrease in the area of jaw structures seen
in zebrafish, although not a finding observed in patients, is
notable given the high expression of WARP in chondro-
cytes (Fitzgerald et al., 2002).
In summary, we describe a novel autosomal-recessive
condition whereby biallelic VWA1 variants lead to a her-
editary non-length dependent motor neuropathy. Support
for this genotype-phenotype correlation includes experi-
ments using two different model organisms, an excess of
homozygous founder alleles and by genetic co-segregation
in one large Afghani kindred. Our detailed clinical charac-
terization of the present patient cohort will facilitate tar-
geted testing on suitable patient cohorts and extrapolation
from 100KGP suggests this gene may explain up to 1% of
unsolved cases of sporadic and hereditary neuropathy in
European populations. Reassessment of unsolved exomes
using lower QC filters at this locus may yield additional
diagnoses.
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Ibá~nez, Rob Jackson, Louise J. Jones, Dalia Kasperaviciute,
Melis Kayikci, Athanasios Kousathanas, Lea Lahnstein, Kay
Lawson, Sarah E. A. Leigh, Ivonne U. S. Leong, Javier F.
Lopez, Fiona Maleady-Crowe, Joanne Mason, Ellen M.
McDonagh, Loukas Moutsianas, Michael Mueller, Nirupa
Murugaesu, Anna C. Need, Peter O’Donovan, Chris A.
Odhams, Andrea Orioli, Christine Patch, Mariana
Buongermino Pereira, Daniel Perez-Gil, Dimitris
Polychronopoulos, John Pullinger, Tahrima Rahim,
Augusto Rendon, Pablo Riesgo-Ferreiro, Tim Rogers, Mina
Ryten, Kevin Savage, Kushmita Sawant, Richard H. Scott,
Afshan Siddiq, Alexander Sieghart, Damian Smedley,
Katherine R. Smith, Samuel C. Smith, Alona Sosinsky,
William Spooner, Helen E. Stevens, Alexander Stuckey,
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